How are countries in sub-Saharan African monitoring the impact of programmes to prevent vertical transmission of HIV?

Ameena Goga and colleagues describe how five countries in sub-Saharan Africa are monitoring the effectiveness of national programmes to prevent vertical transmission of HIV.

Vertical transmission of HIV can occur during pregnancy, delivery, or through breast feeding. The main driver of vertical transmission is a high maternal viral load. Between 2002 and 2016, low and middle income countries (LMICs) in sub-Saharan Africa with high HIV prevalence improved their policies to prevent vertical transmission of HIV. In 2002, national policies recommended single dose nevirapine at the onset of labour, with limited or no breast feeding. By 2016, all Global Plan priority countries in sub-Saharan Africa (where 90% of the world’s HIV positive pregnant women live) had adopted Option B+ with promotion of breast feeding. Option B+ was a dramatic policy change recommending lifelong triple antiretroviral therapy (ART) for all pregnant and lactating women living with HIV. The aim is to protect the child from HIV infection, ensure the mother’s future health, and prevent horizontal transmission of HIV.

Monitoring country level effectiveness of these policy changes is critical, both to ensure they are making a difference to people’s lives and to track progress towards achieving global goals. These goals include the Sustainable Development Goal of ending the AIDS epidemic by 2030; the Global Plan goals of reducing new childhood HIV infections by 90% and HIV related child deaths by more than 50%; and the goal of eliminating transmission of HIV between a mother and her child so that the transmission rate at the end of breast feeding is less than 5% and new paediatric HIV infections are ≤50 per 100 000 live births. Such monitoring is particularly important in LMICs where HIV prevalence is high and where health systems are often weak or stretched beyond capacity.

The World Health Organization recommends three methods to measure programme effectiveness: statistical modelling, surveys or surveillance, and analysis of routine programme data (table 1). This paper looks at how five countries with high HIV prevalence, prioritised for elimination of vertical transmission, have translated global guidance on monitoring prevention programme effectiveness into action.

Our analysis is based on document reviews, peer reviewed publications, reports, and a consultation convened by the South African Medical Research Council in 2016. Representatives from five countries (Kenya, Malawi, South Africa, Uganda, and Zimbabwe) attended the consultation, alongside colleagues from key multilateral agencies including the Joint United Nations Programme on HIV and AIDS (UNAIDS), WHO, the Interagency Task Team on the Prevention and Treatment of HIV Infection in Pregnant Women, Mothers, and their Children, and Unicef.

Country approaches and lessons learnt

Statistical modelling

Models are mathematical equations that can be used to predict outcomes that are difficult to measure directly, such as national HIV incidence and vertical transmission of HIV. Spectrum is a suite of user friendly, easily implementable, regularly updated, free models that support decision making by policy makers (www.avenirhealth.org/software-spectrum.php). Spectrum consists of several software models including the Lives Saved Tool, which focuses on child survival, and the Aids Impact Model (AIM). Other HIV related models, outside of the Spectrum suite, include the Asian Epidemic model, the Thembisa model (which models the South Africa epidemic), and the Global Burden of Disease (GBD) estimates, drawn from vital registration systems. Until now, however, GBD data have not been used to track effectiveness of prevention of vertical transmission. Only Spectrum is available for use by country teams, who are trained regularly, allowing country level tracking and intercountry comparison. The Spectrum AIM uses HIV sentinel and population based surveillance data and programme data in demographic models to calculate estimates. It can estimate vertical transmission of HIV, the number of children living with HIV, the number of new HIV infections in children, and HIV related mortality. Estimates, however, are only as valid as the data and assumptions that go into the models. Input data are usually drawn from prevalence in high risk groups and an estimation of the proportion of the population in these groups. Spectrum software is used by national programmes and UNAIDS to prepare estimates for 161 countries, including Kenya, Malawi, South Africa, Uganda, and Zimbabwe.

In these countries the Spectrum model is used to estimate early (six weeks post-delivery) and long term (six weeks to 24 months) effectiveness of vertical transmission prevention programmes. In fact, because no routine cohort monitoring
systems exist in LMICs with high HIV prevalence, modelling has been the only method consistently used to estimate long term prevention of vertical transmission effectiveness. Until routine data sources are more reliable and of better quality, modelling is needed to estimate the impact of HIV programmes. Modelling is also needed to forecast HIV disease burden to inform future health needs and service provision.7

Surveys or surveillance

Guidance from WHO recommends intermittent immunisation clinic surveys, household surveys, or surveillance through demographic surveillance sites to measure the impact of vertical transmission programmes in prevention.4 Immunisation clinic surveys can be conducted at national or subnational level to measure vertical transmission of HIV (up to six weeks post-delivery), number of children living with or exposed to HIV, and vertical transmission of HIV at the end of breast feeding, if children can be followed up at later time points. Immunisation clinic surveys can provide cross sectional and trend data in settings with high immunisation coverage and allow the collection of coverage and outcome data among all children, not only children born to mothers who are known to have HIV and have interacted with prevention programmes.3 9 Immunisation surveys can be expensive, however, especially if more staff need to be hired, and they can underestimate vertical transmission of HIV as recruitment usually occurs after the neonatal period, thus excluding early infections and deaths.

Malawi, South Africa, and Zimbabwe have conducted cross sectional surveys at immunisation clinics to measure prevention of vertical transmission effectiveness (table 2), but only Zimbabwe and South Africa have generated nationally representative estimates. These surveys are designed to enrol a clinic attending population of mother-infant pairs, regardless of HIV status and interaction with prevention services (table 1). This mitigates selection bias, enrolling mothers of unknown HIV status and recently diagnosed mothers. Measurements have included infant HIV exposure, presumed or actual maternal HIV positivity, vertical transmission of HIV, uptake of prevention interventions, adherence to maternal ART, and uptake of routine maternal and child healthcare (table 1).

When designing clinic based surveys, researchers need to plan for the return of the mother’s and infant’s HIV test results and need to link participants to appropriate care, as it is unethical for these surveys to be anonymised or unlinked.

In Malawi, during 2011, a survey was conducted in immunisation clinics within four of the 28 districts; these four districts were purposively selected to reflect regional diversity.3 10 Of the 5068 samples included in the analysis from infants less than 3 months, 7-12 months, and 12+months after birth), differential vertical transmission of HIV by maternal CD4 count, and the effects of incident infection, maternal ART adherence, and feeding, and to population HIV estimates

| Method | Strengths | Limitations |
| --- | --- | --- |
| Statistical modelling (Spectrum model, for example) | ● Easy to implement | ● Requires reliable input data. Estimates are, therefore, only as valid and up to date as the data they use |
| | ● Estimates for previous years can be updated | |
| | ● Provides data for country reports | |
| | ● Use of a similar methodology across years enables inter-year comparison and tracking of progress | |
| | ● Estimates perinatal vertical transmission of HIV, postnatal prevention of vertical transmission, child survival by time of infection (perinatally, under 6 months, 7-12 months, and 12+months after birth), differential vertical transmission of HIV by maternal CD4 count, and the effects of incident infections and new prophylaxis options | |
| Cross sectional immunisation clinic survey follow-up | ● Early immunisation uptake | ● Survival bias—no capture of mothers or babies that died |
| | ● Can capture known and unknown HIV exposed infants and HIV unexposed infants | ● Selection bias—does not capture mothers who do not seek facility based care |
| | ● Can link mothers and babies to HIV related care | ● Can be expensive to implement if data collectors need to be hired and transported to facilities |
| | ● Can be set up for national, provincial, and district level estimates | |
| Health and demographic sentinel surveillance | ● Allows linking of mother-baby pairs and measurement of long term outcome | ● Resource intensive (time, human resources, and cost) |
| | ● Can obtain final vertical transmission of HIV outcomes and relate it to ART and feeding, and to population HIV estimates | ● Depending on site selection methods, may not always be nationally representative |
| Population based impact surveys | ● Generalisable to whole population | ● Needs large sample size |
| | ● Collect other measures of programme outputs and behaviours | ● Requires HIV status of mother and infant |
| | ● Already exist in the form of demographic and health surveys or multiple indicator cluster surveys | ● Expensive to implement |
| | | ● Existing surveys have multiple modules and outcomes and there are few resources for additional questions and blood tests for mother-infant pairs |
| Use of routine programmatic data | Routine early infant diagnosis (EID) and child HIV testing data from laboratory | ● EID laboratory databases usually exist | |
| | | ● Needs to be coupled with estimated number or percentage of children with no HIV test and their outcomes, to obtain a national estimate | |
| | | ● EID data are not always nationally representative and exclude HIV positive mothers who do not know they are positive | |
| | | ● Biased from health seeking behaviour | |
| | | ● Survival bias, as cannot include children who died | |
| | | ● EID does not tackle final transmission, and cannot link mother to child without unique identifiers | |
| Cohort follow-up | ● Allows linking of mother-baby pairs and measurement of long term outcome | ● Attraction to follow-up necessitates assumptions during analysis | |
| | | ● Can obtain final vertical transmission of HIV outcomes and relate it to ART and feeding | |
| | | ● Difficult to trace without unique identifiers | |
| | | ● Needs functional longitudinal registers | |
| | | ● Resource intensive (time, human resources, and cost) | |
Table 2 How Kenya, Malawi, South Africa, Uganda, and Zimbabwe are monitoring impact of prevention of vertical transmission programmes

| Country          | Statistical modelling (such as Spectrum) | Immunisation clinic survey and follow-up | Health and demographic surveillance site (HDSS) | Population based surveys (community based) | Routine monitoring using EID testing data from laboratory | Routine programmatic cross sectional facility based data | Cohort follow-up |
|------------------|-----------------------------------------|----------------------------------------|-----------------------------------------------|-------------------------------------------|-----------------------------------------------------------|---------------------------------------------------------|------------------|
| Kenya            | Used routinely to generate estimates for national and global progress reports | | One site, Karonga HDSS, currently exists and participates in the in depth network. Two sites, Nairobi urban cohort study and Kisumu study in Siaya and Rarieda districts of Kenya, participate in the Network for Analysing Longitudinal Population-based HIV/AIDS data on Africa, coordinated by the London School of Hygiene and Tropical Medicine. No data generated yet on prevention of vertical transmission impact from these sites | Used, but data on children are aggregated into 0-14 years. No data generated yet on prevention of vertical transmission impact from these surveys | A national EID database has been in place for more than 10 years and is used for prevention of vertical transmission effectiveness monitoring | Used to estimate programme coverage along the steps of prevention of vertical transmission care | Used for HIV exposed infants’ cohort monitoring and maternal ART monitoring |
| Malawi           | Used to measure early prevention of vertical transmission effectiveness in four purposely selected districts out of 28 | Nairobi HDSS, Kilifi HDSS, Mombasa HDSS, Kombewa HDSS, and Kisumu HDSS sites currently exist and participate in the in depth network. No data generated yet on prevention of vertical transmission impact from these sites | | | Routine data are collected quarterly and used for bottleneck analysis and community dialogue to improve systems for retention and care | Paper based systems have been introduced |
| South Africa     | Used to measure early prevention of vertical transmission impact at 4-8 weeks, three times in three successive nationally representative surveys, June-December 2010, August 2011-March 2012, and October 2012-May 2013, with follow-up of HIV exposed infants until 18 months between October 2012 and September 2014 | Dikgale HDSS, Agincourt HDSS, and ARHI HDSS sites currently exist and participate in the in depth network. No data generated yet on prevention of vertical transmission impact from these sites | | | Collated annually to monitor PCR positivity from laboratory test results | In the process of being scaled up |
| Uganda           | - | Iganga/Mayuge HDSS, Kyamulibwa HDSS, and Rakai HDSS sites currently exist and participate in the in depth network. Data from the Iganga/Mayuge HDSS has been used to estimate prevention of vertical transmission effectiveness and the potential impact of interventions | | | Used in district implementation plans and for continuous quality improvement | Electronic systems are in the process of being scaled up |
| Zimbabwe         | Used to measure early prevention of vertical transmission effectiveness in one nationally representative survey, with follow-up of HIV exposed infants until 18 months | - | - | | - | - | Electronic systems are in the process of being developed |

Indications for each method
- Consistently used to measure long term prevention of vertical transmission effectiveness
- Used for intermittent prevention of vertical transmission impact assessment, to corroborate modelling and laboratory data

Lessons learnt
- Can be expensive to implement in weak health systems where additional staff may be needed or existing staff additional remunerated
- Including prevention of vertical transmission impact monitoring in demographic and health surveys is not always feasible, given the vast focus of HDSS activities
- Population based HIV impact assessments an excellent tool but it is not always easy to analyse the 0-14 year age group and relate these data to prevention of vertical transmission impact
- Routine laboratory data sources provided similar estimates as surveys and laboratory data on early vertical transmission of HIV
- DHS data quality needs strengthening and improvement. Involvement of communities improves data quality
- Longitudinal monitoring is key to measuring long term prevention of vertical transmission effectiveness but needs unique identifiers and tracking systems within clinics and communities.

ART, antiretroviral therapy; DHS, District Health Information System; EID, early infant diagnosis; PCR, polymerase chain reaction.
vertical transmission of HIV

months old, 15.1% (95% confidence interval, 14.1 to 16.1) were HIV antibody positive. Vertical transmission of HIV was 8.5% (95% CI, 6.6 to 10.7) with significant district level differences.

In South Africa, three nationally and provincially representative surveys were conducted at immunisation service points between 2010 and 2013, during the implementation of two different policies to prevent vertical transmission of HIV. The surveys demonstrated a reduction in vertical transmission of HIV from an estimated >25% in the absence of vertical transmission prevention interventions to 2.6% in 2012-13; vertical transmission of HIV risk differed by prevention of vertical transmission regimen. The South Africa surveys were expensive to implement; survey data collectors were hired because health facility staff were overburdened and could not incorporate these activities into their daily work. In 2012-2014 longitudinal follow-up of HIV exposed infants was conducted until 18 months to assess long term prevention of vertical transmission effectiveness. Although South Africa implements the regular South Africa Demographic and Health Survey, by 2016 the survey aims were already wide and questionnaires long; thus, monitoring the effectiveness of vertical transmission prevention using this survey has not been feasible.

In Zimbabwe, a nationally representative survey to measure effectiveness of vertical transmission prevention was conducted with 18 month follow-up of mother-infant pairs from facility to community. Verbal autopsies were conducted to understand infant deaths. Cumulative vertical transmission of HIV risk by 18 months was 7%, and data on the differential vertical transmission risk by maternal prevention regimen and infant birth weight have been published. Unlike in South Africa, the Zimbabwean survey was implemented by health facility staff who received a small allowance for their efforts, making the Zimbabwean survey less expensive.

Household surveys and population based HIV impact assessments provide community level data on the HIV epidemic, obviating the inherent selection bias in facility based surveys (table 2). They have great potential for periodically monitoring the effectiveness of vertical transmission prevention programmes every three to five years in settings where adult HIV prevalence is greater than 2%. The Ugandan, Malawian, and Zimbabwean impact assessments included 10652, 9952, and 9627 children aged 0-14, respectively, but analyses have not yet focused on the 0-14 year group, and have not yet been used to estimate vertical transmission of HIV. The wide paediatric age range in current survey designs restricts their reliability and validity for monitoring prevention programme impact.

Monitoring prevention of vertical transmission through longitudinal surveillance at demographic surveillance sites is theoretically possible. Setting sites up is expensive, however, making the use of existing sites for vertical transmission prevention monitoring easier and less expensive. Although demographic surveillance sites exist in four of the five countries (table 2), as far as we are aware these data have only been used to measure effectiveness of prevention of vertical transmission in Uganda. Using data from 68 000 people from 12 000 households, Larsson and colleagues modelled the risk of vertical transmission of HIV among 771 pregnant women in Uganda. They also modelled the effect of improved prevention coverage on vertical transmission of HIV, demonstrating that 100% HIV testing coverage or 100% ART coverage reduces vertical transmission of HIV at birth from 13.4% to 9.6% and 11% respectively. Full (100%) coverage of antenatal clinic attendance and HIV testing and ART reduces vertical transmission of HIV to 5.4% at birth.

Using programme data to monitor prevention effectiveness

WHO recommends three sources of routine data to monitor the impact of vertical transmission prevention programmes, namely routine early infant diagnosis laboratory data; retrospective or prospective cohort data; and case reporting. However, most high HIV prevalence settings in LMICs lack systems for routine cohort monitoring and rely on routine cross sectional data to monitor prevention effectiveness.

Cross sectional routine data

Routine programme data are usually available at facility, regional, and national levels (table 2), and they are used in Kenya, Malawi, Uganda, and South Africa to assess pregnant women’s access to HIV testing, HIV positive pregnant women’s access to ART, HIV exposed infants’ access to HIV testing, and infant HIV positivity (table 2). In Malawi, data are also collected on ART initiation and retention at 12, 24, and 36 months post-delivery, among pregnant women with HIV, and vertical transmission of HIV at 6 weeks, 12 months, and 24 months post-delivery. The reports are collected quarterly and used to identify missed opportunities, implement continuous quality improvement, and enhance retention in care.

A case study in Malawi demonstrated that involving community leaders, health surveillance assistants, and healthcare personnel in data review increased programme effectiveness. In South Africa, District Health Information System (DHIS) and National Health Laboratory Services data are reviewed regularly and reported on at least annually. DHIS data demonstrate significant increases in access to maternal ART with concomitant decreases in early polymerase chain reaction (PCR) positivity at six weeks post-delivery over the past five years. Although routine data are readily available, data accuracy is low. South Africa, Malawi, Uganda, and Kenya also use laboratory data to document trends in PCR positivity. Recent analyses in South Africa demonstrate comparability between laboratory generated and survey generated vertical transmission of HIV estimates. Laboratory data cannot, however, provide information on drivers of vertical transmission as laboratory forms do not capture maternal risk factors, exposure to prevention interventions, or infant feeding patterns, and rely on clinicians to complete information such as infant age. Furthermore, laboratory data need to be de-duplicated, as they often contain repeat infant HIV tests.

Cohort monitoring

Routine cohort monitoring facilitates the tracking of long term (six weeks to 24 months) prevention of vertical transmission outcomes (table 1). Kenya, Malawi, and Uganda have piloted cohort monitoring of mothers on ART and HIV exposed infants from birth (table 2). Such monitoring enhances maternal retention at 3, 6, and 12 months, as missed opportunities are recognised easily and corrective action can be taken at clinic and community levels. In Uganda, the HIV Exposed Infants Birth Cohort Analysis monitors HIV exposed infants’ service uptake at critical time points (6 weeks, 9 and 18 months) and outcomes at 9 and 18 months. Over three years of implementation of the analysis, the proportion of HIV exposed infants retained in care at 18 months increased from 83% in 2012 to 93% in 2014 (personal communication, Linda Nabitaka, Ministry of Health, Kampala, Uganda).

Conclusions

Countries have mainly used modelling with Spectrum software, immunisation clinic
surveys, and routine cross sectional data to monitor vertical transmission of HIV prevention programme effectiveness. With recent expansion to routine cohort monitoring in three countries, however, several additional opportunities exist to monitor programmes. These include population-based HIV impact assessments, health and demographic sentinel surveillance, demographic and health surveys, and laboratory data. There is a critical need to strengthen routine cohort monitoring as this is the most sustainable approach to measure long term effectiveness of vertical transmission prevention programmes.

Contributors and sources: AG conceptualised the paper and led the writing. SW provided information about Zimbabwe. RW provided information about Kenya. ME and WN provided information about Malawi. LN provided information about Uganda. WC, YS, and VP provided information about South Africa. All authors read the paper, contributed to all drafts, and approved the final version of the paper.

Competing interests: We have read and understood BMJ policy on declaration of interests and have no relevant interests to declare. This paper was funded by the South African Medical Research Council (SAMRC). The views expressed in this paper are not the views of either organisation, but of the authors.

Provenance and peer review: Commissioned; externally peer reviewed.

These articles are part of a series proposed by the South African Medical Research Council and commissioned by The BMJ, which retained full editorial control over external peer review, editing, and publication. Open access fees are funded by SAMRC.

Ameena Goga, chief specialist scientist, deputy director1
Yagyeswar Singh, senior scientist1
Debra Jackson, technical adviser14
Solomon Mukungunugwa, deputy national coordinator7
Rose Wafula, PMTCT programme manager9
Michael Eiya, PMTCT coordinator2
Wingston Felix Ng’ambi, lecturer in epidemiology9
Linda Nabataka, medical officer9
Witness Chirinda, specialist scientist13
Sanjana Bhardwaj, technical adviser10
Shaflqf Essajee, senior adviser11
Chika Hayashi, technical adviser11
Yogan Pillay, deputy director general12
1Health Systems Research Unit, Department of Health Systems and Policy, College of Medicine, Lilongwe Campus, University of Malawi, Lilongwe, Malawi
2Ministry of Health, Kampala, Uganda
3Unicef Nigeria, formerly Unicef Pretoria, South Africa
4Data and Analytics Section, Unicef, New York, USA
5National AIDS and TB, MCWHN, National Department of Health, Pretoria, South Africa
6AIDS/HIV, TB, MCWHN, National Department of Health, Pretoria, South Africa
7Ministry of Health, HIV and AIDS Department, Lilongwe, Malawi
8Health Economics and Policy Unit, Department of Health Systems and Policy, College of Medicine, Lilongwe Campus, University of Malawi, Lilongwe, Malawi
9Ministry of Health, Kampala, Uganda
10Unicef Nigeria, formerly Unicef Pretoria, South Africa
11Data and Analytics Section, Unicef, New York, USA
12HIV/AIDS, TB, MCWHN, National Department of Health, Pretoria, South Africa
13Data and Analytics Section, Unicef, New York, USA
14Ministry of Health, Pretoria, South Africa

Correspondence to: A Goga Ameena.Goga@mrc.ac.za

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

1 World Health Organization. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2012. www.who.int/hiv/pub/mtct/programmatic_update_2012.pdf
2 UNAIDS. On the fast track to an AIDS free generation: the incredible journey of the global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. 2016. www.aidsdatahub.org/fast-track-aims-free-generation-2015-2016
3 World Health Organization. Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV and syphilis. 2014. www.who.int/hiv/pub/emtct-validation-guidance/en
4 World Health Organization. A short guide on methods: measuring the impact of national PMTCT programmes. 2012. www.who.int/hiv/pub/mtct/national_pmtct_guide/en
5 Johnson L, Dorrington R. Thembisa version 4.1: a model for evaluating the impact of HIV/AIDS in South Africa. 2018. www.thembisa.org/content/file3/Thembisai_Report.pdf
6 GBD 2015 HIV Collaborators. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet 2016;387:361-87. doi:10.1016/S0140-6736(16)30087-X
7 Stover J, Brown T, Puckett R, Peerapatanakorn W. Updates to the Spectrum/Estimations and Projections Package model for estimating trends and current values for key HIV indicators. AIDS 2013;27:1877-81. doi:10.1097/QAD.0000000000000132
8 Goga AE, Dingh TH, Jackson DJ, et al, South Africa PMTCT Evaluation (SAPMCTE) Team. Population-level effectiveness of PMTCT Option A on early mother-to-child (MTCT) transmission of HIV in South Africa: implications for eliminating MTCT. J Glob Health 2016;6:020405. doi:10.7189/jogh.06.020405
9 Goga AE, Dingh TH, Jackson DJ, et al, South Africa PMTCT Evaluation Team. First population-level effectiveness evaluation of a national programme to prevent HIV transmission from mother to child, South Africa. J Epidemiol Community Health 2015;69:240-8. doi:10.1136/jech-2014-204535
10 Sinuwa MA, Sodinda EJ, Wadoorah-Kabondo NV, et al. Evaluating the impact of prevention of mother-to-child transmission of HIV in Malawi through immunization clinic-based surveillance. PLoS One 2014;9:e100741. doi:10.1371/journal. pone.0100741
11 Goga A, Sherman G, Chirinda W, et al. Eliminating mother-to-child transmission of HIV in South Africa, 2002-2016: progress, challenges, and the Last Mile Plan. South African Health Reviews 2017. www. host.org.za/publications/South%20Africa%20 Health%20Reviews/13_Eliminating%20mother%20 to%20child%20transmission%20in%20HIV%20in%20South%20Africa%202002%20to%202016_progress_challenges%20and%20the%20Last%20Mile_Plan.pdf
12 Dingh TH, Mushavi A, Shiraishi RW, et al. Impact of timing of antiretroviral treatment and birth weight on mother-to-child human immunodeficiency virus transmission: findings from an 18-month prospective cohort study. A sample of mother–infant pairs during the transition from option A to option B+ in Zimbabwe. Clin Infect Dis 2018;66:576-85. doi:10.1093/cid/cixb20
13 Ugandan Government. Uganda population based HIV impact assessment. 2015. http://library.health.go.uk/publications/service-delivery-diseases-control-prevention-communicable-diseases/hiv/aids/uganda-0
14 Malawi Ministry of Health. Malawi population based HIV impact assessment. 2016. http://phia.icap.columbia.edu/wp-content/uploads/2016/09/MALAWI-Factsheet_Final.pdf
15 Zimbabwe Ministry of Health and Child Care. Zimbabwe population based HIV impact assessment. 2016. http://phia.icap.columbia.edu/wp-content/uploads/2016/11/ZIMBABWE_Factsheet_Final.pdf
16 Larsson EC, Ekstrom AM, Parwo G, et al. Prevention of mother-to-child transmission of HIV in rural Uganda: modelling effectiveness and impact of scaling-up PMTCT services. Glob Health Action 2015;8:26308. doi:10.3402/gpha.v8.26308
17 UNICEF. Together we can improve: a case study on joint community-facility review of PMTCT dashboards in Malawi. 2016. www.pedaids.org/resource/a-case-study-on-joint-community-facility-review-of-pmtct-dashboards-in-malawi
18 Sherman G, Lillian R, Bhardwaj S, Candy S, Barron P. Laboratory information system data demonstrate successful implementation of mother-to-child transmission programme in South Africa. S Afr Med J 2014;104(Suppl 1):235-8. doi:10.7196/SAMJ.7598
19 Mwaiss N, Peer N, English R. District Health Barometer. 2016. www.hst.org.za/sites/default/files/Complete_DHB_2015_16_linked.pdf
20 Nicol E, Dudley L, Bradshaw D. Assessing the quality of routine data for the prevention of mother-to-child transmission of HIV. An analytical observational study in two health districts with high HIV prevalence in South Africa. Int J Med Inform 2016;95:60-70. doi:10.1016/j.ijmedinf.2016.09.006
21 Sherman G, Haeri Mazandarani A, Barron P, et al. Toward elimination of mother-to-child transmission of HIV in South Africa: how best to monitor early infant infections within the Prevention of Mother-to-Child Transmission Program. J Glob Health 2017;7:010701. doi:10.7189/jogh.07.010701
22 Mayo F, Haeri Mazandarani A, Barron P, et al. Introduction of Routine HIV Birth Testing in the South African National Consolidated Guidelines. Pediatr Infect Dis J 2018;37:559-63. doi:10.1097/INF.0000000000001840

Cite this as: BMJ 2019;364:l660

BMJ first published as 10.1136/bmj.l660 on 12 April 2019. Downloaded from http://www.bmj.com/ on 12 April 2019 by guest. Protected by copyright.